S-1/A: Nuwellis Files Amendment No. 3 to Form S-1 Registration Statement

Nuwellis, Inc. has filed Amendment No. 3 to its Form S-1 registration statement, primarily to include an updated Exhibit 5.1, with no other changes to the prospectus.

Summary

• Nuwellis, Inc. filed Amendment No. 3 to its Form S-1 registration statement (Registration No. 333-276562) with the Securities and Exchange Commission on February 8, 2024.
• The amendment updates Exhibit 5.1, with no other modifications to the registration statement or prospectus.
• The registration statement relates to the offer and sale of up to 16,666,666 units, each consisting of one share of common stock, one Series A warrant, and one Series B warrant.
• It also covers the offer and sale of up to 16,666,666 pre-funded units, each consisting of one pre-funded warrant, one Series A warrant, and one Series B warrant.
• Additionally, the registration statement includes up to 49,999,998 shares of common stock issuable upon the exercise of the Series A, Series B, and pre-funded warrants.
• The warrants are being issued under a warrant agency agreement with Equiniti Trust Company, LLC.
• The units and pre-funded units will be sold under a placement agency agreement with Lake Street Capital Markets, LLC and Maxim Group LLC.
• The company has estimated expenses of issuance and distribution to be $374,254, including SEC registration fees, FINRA filing fees, legal fees, accounting fees, and other miscellaneous expenses.
• The company's certificate of incorporation and bylaws provide indemnification for directors and officers to the fullest extent authorized by the Delaware General Corporation Law.
• On June 19, 2023, Nuwellis granted a warrant to DaVita, Inc. to purchase up to 1,289,081 shares of common stock at an exercise price of $3.2996 per share, subject to vesting milestones related to the Supply and Collaboration Agreement between the two companies.

Sentiment

Score: 6

Explanation: The document is a regulatory filing, so the sentiment is neutral. It outlines a potential capital raise and legal aspects, but doesn't express strong positive or negative views.

Positives

• The company has secured agreements with Lake Street Capital Markets, LLC and Maxim Group LLC for placement agency services, potentially facilitating the sale of units and pre-funded units.
• The company has indemnification agreements in place for its directors and executive officers, providing protection against certain liabilities.
• The company has a supply and collaboration agreement with DaVita, Inc., which includes a warrant grant that could lead to increased revenue if milestones are met.

Risks

• The opinion of Honigman LLP regarding the validity of the warrants is subject to limitations, including bankruptcy laws and general principles of equity.
• The enforceability of certain provisions within the warrants, such as those related to liquidated damages or waivers of rights, may be limited by legal and public policy considerations.
• The indemnification of directors and officers for liabilities arising under the Securities Act may be unenforceable as against public policy, according to the Securities and Exchange Commission.

Future Outlook

The document outlines the potential offer and sale of securities, but does not provide specific forward-looking statements regarding the company's future financial performance or business operations.

Industry Context

This filing is a standard step for companies seeking to raise capital through the issuance of securities. The collaboration with DaVita, Inc. suggests a focus on expanding the use of Nuwellis' Aquadex system in the treatment of congestive heart failure.

Comparison to Industry Standards

• The structure of the offering, including units with common stock and warrants, is a common practice among small-cap and micro-cap companies seeking to raise capital.
• The collaboration with DaVita is similar to other medical device companies partnering with large healthcare providers to expand market reach and adoption of their technologies.
• The legal opinions and indemnification agreements are standard components of securities registration statements.

Related Party Transactions

• The grant of a warrant to DaVita, Inc. is a related party transaction due to the Supply and Collaboration Agreement between the two companies.

Stakeholder Impact

• Shareholders may experience dilution if the warrants are exercised and new shares are issued.
• The capital raise could provide the company with additional funds to support its operations and growth initiatives.
• The collaboration with DaVita could benefit patients by expanding access to Nuwellis' Aquadex therapy.

Next Steps

• The company will proceed with offering and selling the securities as described in the registration statement and related prospectus.
• The company will enter into a warrant agency agreement with Equiniti Trust Company, LLC.
• The company will work with Lake Street Capital Markets, LLC and Maxim Group LLC to facilitate the placement of the securities.

Key Dates

Keywords

S-1, registration statement, units, warrants, common stock, pre-funded units, placement agency agreement, securities, Nuwellis, DaVita